ClinConnect ClinConnect Logo
Search / Trial NCT05403385

Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Launched by ITEOS THERAPEUTICS · May 31, 2022

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Non Squamous Nsclc Second Line 2 L Adenosine Immunotherapy

ClinConnect Summary

This clinical trial is studying a new treatment option for patients with advanced non-small cell lung cancer (NSCLC) that has not responded to previous treatments. The researchers want to find the best dose of a drug called inupadenant when it is combined with two standard chemotherapy drugs, carboplatin and pemetrexed. They will then compare how well this combination works and how safe it is compared to the standard chemotherapy treatments alone.

To participate in this trial, patients need to have a confirmed diagnosis of metastatic (stage IV) or locally advanced (stage III) nonsquamous NSCLC. They should have measurable cancer and have previously been treated with an anti-PD(L)1 therapy for at least 12 weeks. Eligible participants can be of any age between 65 and 74, and both men and women can join. Once enrolled, participants will receive the new treatment and be closely monitored for any side effects and how well the treatment is working. It’s important to note that patients with certain health conditions or those who are pregnant or breastfeeding cannot participate in this trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology
  • Measurable disease as defined by RECIST v1.1
  • PD-L1 expression status available at or after the time of diagnosis. All levels of expression are eligible.
  • Existing biopsy taken within 4 years prior to entering trial or provide fresh biopsy where safe and feasible
  • At least 12 weeks of treatment with only 1 anti-PD-(L)1 agent (mono or with IO combo) in the metastatic setting, OR at least 12 weeks of anti-PD-(L)1 agent (mono or with IO combo) following CRT in the unresectable, Stage III setting
  • ECOG performance status of 0 to 1.
  • Exclusion Criteria:
  • Symptomatic central nervous system (CNS) metastases or leptomeningeal disease.
  • EGFR, ALK, or ROS1 mutation.
  • Autoimmune disease requiring systemic treatment or immunodeficiency requiring concurrent use of systemic immunosuppressants or corticosteroids
  • Hepatitis B or C infection unless adequately treated with no detectable viral load; Human immunodeficiency virus (HIV) unless well-controlled disease on therapy.
  • History of life-threatening toxicity related to prior immune therapy
  • Uncontrolled or significant cardiovascular disease
  • Pregnant or breast-feeding
  • Lack of agreement to use highly effective method of contraception during treatment and for 6 months after the last administration of chemotherapy

About Iteos Therapeutics

Iteos Therapeutics is a biopharmaceutical company dedicated to advancing innovative therapies for cancer treatment through the development of immune-oncology approaches. With a focus on harnessing the body’s immune system to combat tumors, Iteos is committed to discovering and delivering transformative therapies that improve patient outcomes. The company leverages cutting-edge science and a robust pipeline of drug candidates, aimed at addressing unmet medical needs in oncology. Iteos Therapeutics is driven by a team of experienced professionals and a collaborative ethos, aiming to lead the next generation of cancer care.

Locations

Tampa, Florida, United States

Lyon, , France

Lausanne, , Switzerland

Tampa, Florida, United States

Orange City, Florida, United States

Dijon, , France

Fayetteville, Arkansas, United States

Alicante, , Spain

Badajoz, , Spain

Lugo, , Spain

Milano, , Italy

Santander, , Spain

Barcelona, , Spain

Sutton, , United Kingdom

Valencia, , Spain

Nantes, , France

Chemnitz, , Germany

Brescia, , Italy

A Coruña, , Spain

Heidelberg, , Germany

Gettysburg, Pennsylvania, United States

Mons, , Belgium

Avellino, , Italy

Lucca, , Italy

Saint Mandé, , France

Dijon, , France

Roeselare, , Belgium

Madrid, , Spain

Namur, , Belgium

Hasselt, , Belgium

Mons, , Belgium

Whittier, California, United States

Brampton, Ontario, Canada

Castellón De La Plana, , Spain

Warszawa, Mazowieckie, Poland

Florham Park, New Jersey, United States

Bordeaux, , France

Gent, , Belgium

Palma De Mallorca, Illes Balears, Spain

Créteil, , France

Bordeaux, , France

Namur, , Belgium

Tyler, Texas, United States

Omaha, Nebraska, United States

Palma De Mallorca, Illes Balears, Spain

Zürich, , Switzerland

Fayetteville, North Carolina, United States

Mechelen, , Belgium

Canton, Ohio, United States

Omaha, Nebraska, United States

Manresa, , Spain

Fayetteville, North Carolina, United States

Krakow, , Poland

Poznan, , Poland

Pamplona, , Spain

Caen, , France

łódź, , Poland

Olomouc, , Czechia

Marseille, , France

Oświęcim, , Poland

Piła, , Poland

Ourense, , Spain

Praha, , Czechia

Peschiera Del Garda, , Italy

Olsztyn, Warminsko Mazurskie, Poland

Villars Sur Glâne, , Switzerland

Milan, , Italy

Rozzano, , Italy

Barcelona, , Spain

Zürich, , Switzerland

Mechelen, Antwerp, Belgium

Edmonton, Alberta, Canada

Praha 3, , Czechia

Bordeaux, , France

Marseille, , France

Saint Mandé, , France

Giessen, Hessen, Germany

Essen, , Germany

Köln, , Germany

Lowenstein, , Germany

Orbassano, , Italy

Poznan, Wielkopolskie, Poland

Badajoz, , Spain

Coruña, , Spain

Villars Sur Glâne, , Switzerland

Patients applied

0 patients applied

Trial Officials

Iteos Clinical Trials

Study Director

iTeos Belgium SA

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials